pyrazines has been researched along with cyclin d1 in 30 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 12 (40.00) | 29.6817 |
| 2010's | 18 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dai, Y; Grant, S; Pei, XY | 1 |
| Bold, RJ; Fahy, BN; Mortenson, MM; Schlieman, MG; Virudachalam, S | 1 |
| Aggarwal, BB; Gutierrez, AM; Lotan, R; Shishodia, S | 1 |
| Alvarez, JV; Frank, DA; Germain, D; Ishii, Y; Keselman, I; Logothetis, D; Mandeli, J; O'Connell, MJ; Pirkmaier, A; Waxman, S | 1 |
| Ara, G; Chen, Z; Duan, J; Friedman, J; Nottingham, L; Van Waes, C | 1 |
| Germain, D; Ishii, Y; Waxman, S | 1 |
| Aggarwal, BB; Bhutani, M; Guha, S; Kunnumakkara, AB; Nair, AS; Pathak, AK; Sethi, G | 1 |
| Mao, H; Schnellmann, RG; Xing, J; Zhang, Z; Zhuang, S | 1 |
| Asaoku, H; Katayama, Y; Kimura, A; Kuroda, Y; Matsui, H; Mizuno, M; Munemasa, S; Nakaju, N; Nishisaka, T; Ogawa, K; Okikawa, Y; Sakai, A; Tanaka, H; Tsuyama, N | 1 |
| Dawson, MA; Donovan, M; Hertzberg, M; Horvath, N; McLean, CA; Monaghan, K; Opat, SS; Prince, HM; Roberts, AW; Spencer, A; Taouk, Y; Zammit, M | 1 |
| Anderson, KC; Carrasco, R; Chabner, B; Chauhan, D; Chhetri, S; Cirstea, D; Hideshima, T; Ikeda, H; Kiziltepe, T; Mitsiades, C; Mukherjee, S; Munshi, NC; Okawa, Y; Parikh, H; Podar, K; Pozzi, S; Raab, M; Raje, N; Richardson, PG; Rooney, M; Scadden, D; Sharma, S; Vallet, S | 1 |
| Marchi, E; O'Connor, OA; Paoluzzi, L; Scotto, L; Seshan, VE | 1 |
| Bauer, F; Dasanu, CA; Reale, MA | 1 |
| Engelhardt, M; Felthaus, J; Follo, M; Hein, M; Ihorst, G; Ngo, BT; Wäsch, R; Wider, D | 1 |
| Gertz, MA; Tadmor, T | 1 |
| Bornmann, W; Ford, RJ; Li, C; Pham, LV; Priebe, W; Tamayo, AT | 1 |
| Ahn, KS; Jang, HJ; Kim, HJ; Kim, SH; Kim, SM; Na, YS; Park, KR | 1 |
| Andreeff, M; Asou, H; Inaba, T; Jin, L; Kimura, S; Konopleva, M; Kuroda, J; Miida, T; Tabe, Y; Zhou, Y | 1 |
| Anand, M; Armanious, H; Belch, A; Gelebart, P; Lai, R | 1 |
| Bai, QX; Chen, JJ; Huang, GS; Yang, LJ; Zhang, XY; Zhao, H | 1 |
| Amerik, AY; Issaenko, OA | 1 |
| Huang, K; Li, Y; Ma, L; Nie, D; Wang, X; Wu, Y; Xiao, J; Xie, S; Yin, S | 1 |
| Chen, Z; Jung, HJ; McCarty, N | 1 |
| Joshi, KS; Manohar, SM; Shirsath, NP | 1 |
| Doi, T; Fujimi, A; Hashimoto, A; Ishikawa, K; Kanisawa, Y; Matsuno, T; Minami, S; Okuda, T; Uemura, N | 1 |
| Fu, Q; Wang, Y; Zhao, W | 1 |
| Wang, ZQ; Xie, JL; Zhou, XG | 1 |
| Hur, DY; Jin, DH; Kim, D; Kim, JE; Kim, S; Kim, YS; Lee, JI; Lee, WJ; Park, GB; Wu, TC | 1 |
| Huang, XE; Ji, AJ; Ju, WZ; Liu, SL | 1 |
| Cowan, AJ; Frayo, SL; Gopal, AK; Green, DJ; Pagel, JM; Palanca-Wessels, MC; Press, OW | 1 |
1 review(s) available for pyrazines and cyclin d1
| Article | Year |
|---|---|
Targeting the ubiquitin-proteasome pathway in cancer therapy.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cyclin D1; Humans; Multiple Myeloma; Neoplasms; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Ubiquitin | 2007 |
29 other study(ies) available for pyrazines and cyclin d1
| Article | Year |
|---|---|
Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
Topics: Acetylcysteine; Antineoplastic Agents; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cell Survival; Cyclin D1; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Cytosol; Dose-Response Relationship, Drug; Enzyme Inhibitors; Free Radical Scavengers; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Intracellular Membranes; Membrane Glycoproteins; Membrane Potentials; Mitochondria; Multiple Myeloma; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Oxidative Stress; Oxygen; Protease Inhibitors; Proteins; Proteoglycans; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Reactive Oxygen Species; Sodium Oxybate; Syndecan-1; Syndecans; Tumor Suppressor Proteins; Vorinostat; X-Linked Inhibitor of Apoptosis Protein | 2004 |
Targeting BCL-2 overexpression in various human malignancies through NF-kappaB inhibition by the proteasome inhibitor bortezomib.
Topics: Boronic Acids; Bortezomib; Breast Neoplasms; Cyclin D1; Female; Gene Expression Regulation, Neoplastic; Humans; Male; NF-kappa B; Pancreatic Neoplasms; Prostatic Neoplasms; Protease Inhibitors; Pyrazines; Signal Transduction; Transcription, Genetic; Tumor Cells, Cultured | 2005 |
N-(4-hydroxyphenyl)retinamide inhibits invasion, suppresses osteoclastogenesis, and potentiates apoptosis through down-regulation of I(kappa)B(alpha) kinase and nuclear factor-kappaB-regulated gene products.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Small Cell; Carrier Proteins; Cell Growth Processes; Cyclin D1; Cyclooxygenase 2; Down-Regulation; Drug Synergism; Enzyme Activation; Fenretinide; Genes, myc; Humans; I-kappa B Kinase; I-kappa B Proteins; Lung Neoplasms; Membrane Glycoproteins; NF-kappa B; NF-KappaB Inhibitor alpha; Oncogene Protein v-akt; Osteoclasts; Phosphorylation; Promoter Regions, Genetic; Proto-Oncogene Proteins c-myc; Pyrazines; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Transcription Factor RelA; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A | 2005 |
Cyclin D1 overexpression and response to bortezomib treatment in a breast cancer model.
Topics: Animals; Antineoplastic Agents; Apoptosis; bcl-X Protein; Biomarkers, Tumor; Boronic Acids; Bortezomib; Breast Neoplasms; Calcium; Caspase 3; Caspases; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Female; Fluorescent Antibody Technique; Gene Expression Regulation, Neoplastic; Humans; Immunoblotting; In Situ Nick-End Labeling; Mice; Mice, Inbred BALB C; Microarray Analysis; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; STAT3 Transcription Factor; Transplantation, Heterologous; Up-Regulation | 2006 |
Nuclear factor-kappaB p65 small interfering RNA or proteasome inhibitor bortezomib sensitizes head and neck squamous cell carcinomas to classic histone deacetylase inhibitors and novel histone deacetylase inhibitor PXD101.
Topics: Acetylation; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; bcl-X Protein; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Cyclin D1; Cyclin-Dependent Kinase Inhibitor p21; DNA, Neoplasm; Down-Regulation; Drug Resistance, Neoplasm; Enzyme Inhibitors; Head and Neck Neoplasms; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Inhibitor of Apoptosis Proteins; Mice; Mice, SCID; NF-kappa B p50 Subunit; Proteasome Inhibitors; Protein Binding; Pyrazines; RNA, Small Interfering; Sulfonamides; Transcription Factor RelA; Xenograft Model Antitumor Assays | 2007 |
Capsaicin is a novel blocker of constitutive and interleukin-6-inducible STAT3 activation.
Topics: Antineoplastic Agents; Apoptosis; bcl-X Protein; Boronic Acids; Bortezomib; Capsaicin; Caspase 3; Caspase Inhibitors; Cell Line, Tumor; Cell Proliferation; Cyclin D1; DNA; Extracellular Signal-Regulated MAP Kinases; G1 Phase; Humans; Inhibitor of Apoptosis Proteins; Interleukin-6; Janus Kinase 1; Microtubule-Associated Proteins; Multiple Myeloma; Neoplasm Proteins; Phosphorylation; Poly(ADP-ribose) Polymerases; Protein Tyrosine Phosphatases; Proto-Oncogene Proteins c-bcl-2; Pyrazines; STAT3 Transcription Factor; Survivin; Thalidomide; Vascular Endothelial Growth Factor A | 2007 |
Src regulates cell cycle protein expression and renal epithelial cell proliferation via PI3K/Akt signaling-dependent and -independent mechanisms.
Topics: Cell Line; Cell Proliferation; Chromones; Cyclin D1; Cyclin-Dependent Kinase Inhibitor p27; Cyclin-Dependent Kinase Inhibitor p57; Epithelial Cells; Hydrazines; Kidney; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Morpholines; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Pyrazines; Quinolines; Signal Transduction; src-Family Kinases; Up-Regulation | 2008 |
Ectopic cyclin D1 overexpression increases chemosensitivity but not cell proliferation in multiple myeloma.
Topics: Aged; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Cyclin D2; Cyclin-Dependent Kinase Inhibitor p27; Cyclins; Dexamethasone; Female; Humans; Intracellular Signaling Peptides and Proteins; Male; Melphalan; Middle Aged; Multiple Myeloma; Phosphorylation; Pyrazines; Retinoblastoma Protein; Thalidomide; Time Factors; Transfection; Up-Regulation; Vincristine | 2008 |
Clinical and immunohistochemical features associated with a response to bortezomib in patients with multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Cycle; Cohort Studies; Cyclin D1; Cyclin-Dependent Kinase Inhibitor p16; Female; Humans; Immunohistochemistry; Male; Middle Aged; Multiple Myeloma; Prognosis; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Treatment Outcome; Tumor Suppressor Protein p53 | 2009 |
Preclinical activity of P276-00, a novel small-molecule cyclin-dependent kinase inhibitor in the therapy of multiple myeloma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Bone Marrow; Boronic Acids; Bortezomib; Caspases; Cell Adhesion; Cell Cycle; Cell Proliferation; Cyclin D1; Cyclin-Dependent Kinase Inhibitor Proteins; Down-Regulation; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Drug Synergism; Flavones; Gene Expression Profiling; Humans; Insulin-Like Growth Factor I; Interleukin-6; Male; Mice; Mice, SCID; Multiple Myeloma; Oligonucleotide Array Sequence Analysis; Phosphorylation; Pyrazines; Retinoblastoma Protein; Stromal Cells; Transplantation, Heterologous; Tumor Cells, Cultured | 2009 |
The anti-histaminic cyproheptadine synergizes the antineoplastic activity of bortezomib in mantle cell lymphoma through its effects as a histone deacetylase inhibitor.
Topics: Actins; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cyclin D1; Cyproheptadine; Disease Models, Animal; Histamine H1 Antagonists; Histone Deacetylase Inhibitors; Lymphoma, Mantle-Cell; Mice; Protease Inhibitors; Pyrazines | 2009 |
Mantle cell lymphoma arising in a multiple myeloma patient responding to lenalidomide.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Cyclin D1; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Immunocompromised Host; Immunosuppression Therapy; Lenalidomide; Lymphoma, Mantle-Cell; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Proteins; Neoplasms, Second Primary; Pyrazines; Rituximab; Thalidomide; Transplantation, Autologous | 2010 |
Monitoring bortezomib therapy in multiple myeloma: screening of cyclin D1, D2, and D3 via reliable real-time polymerase chain reaction and association with clinico-pathological features and outcome.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Marrow; Boronic Acids; Bortezomib; Cyclin D1; Cyclin D2; Cyclin D3; DNA; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Pilot Projects; Polymerase Chain Reaction; Pyrazines; Salvage Therapy; Survival Rate; Treatment Outcome | 2010 |
Individualizing cancer therapy.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cyclin D1; Humans; Multiple Myeloma; Precision Medicine; Pyrazines; Treatment Outcome | 2010 |
Degrasyn potentiates the antitumor effects of bortezomib in mantle cell lymphoma cells in vitro and in vivo: therapeutic implications.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cells, Cultured; Cyanoacrylates; Cyclin D1; Dose-Response Relationship, Drug; Drug Synergism; Female; Gene Expression Regulation, Leukemic; Humans; Lymphoma, Mantle-Cell; Mice; Mice, SCID; NF-kappa B; Nitriles; Phosphorylation; Proto-Oncogene Proteins c-myc; Pyrazines; Pyridines; Reverse Transcriptase Polymerase Chain Reaction; STAT3 Transcription Factor; Survival Analysis; Xenograft Model Antitumor Assays | 2010 |
Decursin chemosensitizes human multiple myeloma cells through inhibition of STAT3 signaling pathway.
Topics: Apoptosis; Benzopyrans; Boronic Acids; Bortezomib; Butyrates; Caspase 3; Cell Line, Tumor; Cyclin D1; DNA; G1 Phase; Humans; Interleukin-6; Janus Kinase 2; Multiple Myeloma; Phosphorylation; Pyrazines; Signal Transduction; STAT3 Transcription Factor | 2011 |
Antiproliferative and proapoptotic activity of GUT-70 mediated through potent inhibition of Hsp90 in mantle cell lymphoma.
Topics: Antineoplastic Agents; Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; Blotting, Western; Boronic Acids; Bortezomib; Cell Cycle; Cell Proliferation; Coumarins; Cyclin D1; Drug Synergism; Drug Therapy, Combination; Flow Cytometry; HSP90 Heat-Shock Proteins; Humans; Immunoenzyme Techniques; Immunoprecipitation; Lymphoma, Mantle-Cell; Mutation; Oncogene Protein v-akt; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-raf; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2011 |
Constitutive activation of metalloproteinase ADAM10 in mantle cell lymphoma promotes cell growth and activates the TNFα/NFκB pathway.
Topics: ADAM Proteins; ADAM10 Protein; Amyloid Precursor Protein Secretases; Boronic Acids; Bortezomib; Cell Line, Tumor; Cyclin D1; Cyclin-Dependent Kinase Inhibitor p21; Cysteine Proteinase Inhibitors; Enzyme Activation; Female; Humans; Leupeptins; Lymphoma, Mantle-Cell; Male; Membrane Proteins; Palatine Tonsil; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Signal Transduction; Tonsillar Neoplasms; Transcription Factor RelA; Tumor Necrosis Factor-alpha | 2011 |
[Effect of curcumin in combination with bortezomib on proliferation and apoptosis of human multiple myeloma cell line H929 and its mechanism].
Topics: Apoptosis; bcl-2-Associated X Protein; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Curcumin; Cyclin D1; Drug Therapy, Combination; Humans; Multiple Myeloma; NF-kappa B; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Transcription Factor RelA | 2011 |
Chalcone-based small-molecule inhibitors attenuate malignant phenotype via targeting deubiquitinating enzymes.
Topics: Antineoplastic Agents; Apoptosis; Benzylidene Compounds; Boronic Acids; Bortezomib; Breast Neoplasms; Catalytic Domain; Cell Cycle Checkpoints; Cell Proliferation; Cell Survival; Chalcone; Cyclin D1; Cysteine; Dose-Response Relationship, Drug; Endopeptidases; Female; HeLa Cells; Humans; Ovarian Neoplasms; Phenotype; Piperidones; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Tumor Suppressor Protein p53; Ubiquitin Thiolesterase; Ubiquitins | 2012 |
Synergistic/additive interaction of valproic acid with bortezomib on proliferation and apoptosis of acute myeloid leukemia cells.
Topics: Acute Disease; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Proliferation; Cell Survival; Cyclin D1; Drug Synergism; Gene Expression; Histone Deacetylase Inhibitors; HL-60 Cells; Humans; Inhibitory Concentration 50; Leukemia, Myeloid; Proteasome Inhibitors; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; Telomerase; Valproic Acid | 2012 |
Synergistic anticancer effects of arsenic trioxide with bortezomib in mantle cell lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclin D1; Drug Synergism; Humans; Lymphoma, Mantle-Cell; Oxides; Pyrazines | 2012 |
P276-00, a cyclin-dependent kinase inhibitor, modulates cell cycle and induces apoptosis in vitro and in vivo in mantle cell lymphoma cell lines.
Topics: Animals; Antigens, Surface; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Tumor; Cyclin D1; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; Flavones; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; Lymphoma, Mantle-Cell; Mice; Mice, SCID; Neoplasm Proteins; Protein Kinase Inhibitors; Pyrazines; RNA, Small Interfering; Survival Analysis; Xenograft Model Antitumor Assays | 2012 |
[Loss of CD23 expression after bortezomib plus dexamethasone therapy in CCND1/IGH-positive multiple myeloma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclin D1; Dexamethasone; Humans; Male; Multiple Myeloma; Pyrazines; Receptors, IgE | 2013 |
Tetramethylpyrazine inhibits osteosarcoma cell proliferation via downregulation of NF-κB in vitro and in vivo.
Topics: Active Transport, Cell Nucleus; Animals; Antineoplastic Agents; Bone Neoplasms; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; Cyclin D1; Down-Regulation; Female; G1 Phase Cell Cycle Checkpoints; Gene Expression; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Osteosarcoma; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Transcription Factor RelA; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
[Right cervical lymph node enlargement].
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclin D1; Dexamethasone; Diagnosis, Differential; Follow-Up Studies; Histiocytic Necrotizing Lymphadenitis; Humans; Infectious Mononucleosis; Ki-67 Antigen; Lymph Nodes; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Male; Middle Aged; Neck; Pyrazines; SOXC Transcription Factors | 2013 |
Sequential treatment of HPV E6 and E7-expressing TC-1 cells with bortezomib and celecoxib promotes apoptosis through p-p38 MAPK-mediated downregulation of cyclin D1 and CDK2.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Celecoxib; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase Inhibitor p21; Cyclooxygenase 2 Inhibitors; Down-Regulation; Endoplasmic Reticulum Stress; Female; G1 Phase Cell Cycle Checkpoints; Imidazoles; Mice; Mice, Inbred C57BL; Oncogene Proteins, Viral; p38 Mitogen-Activated Protein Kinases; Papillomavirus E7 Proteins; Pyrazines; Pyrazoles; Pyridines; Repressor Proteins; STAT3 Transcription Factor; Sulfonamides; Transcription Factor CHOP; Uterine Cervical Neoplasms | 2014 |
Anti-proliferation effects and molecular mechanisms of action of tetramethypyrazine on human SGC-7901 gastric carcinoma cells.
Topics: Apoptosis; Blotting, Western; Carcinoma; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Cyclin-Dependent Kinase Inhibitor p16; Down-Regulation; Drug Screening Assays, Antitumor; Gene Expression Regulation, Neoplastic; Humans; Neoplasm Proteins; NF-kappa B; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Stomach Neoplasms; Up-Regulation | 2014 |
Bortezomib and fenretinide induce synergistic cytotoxicity in mantle cell lymphoma through apoptosis, cell-cycle dysregulation, and IκBα kinase downregulation.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cyclin B; Cyclin D1; Cyclin D3; Drug Synergism; Fenretinide; G2 Phase Cell Cycle Checkpoints; Humans; I-kappa B Proteins; Lymphoma, Mantle-Cell; NF-KappaB Inhibitor alpha; Pyrazines | 2015 |